Additionally, the results revealed that MTAP/CDKN2AMUT significantly predicted poor DSS (P < 0.0001, HR = 6.921), PFS (P < 0.0001, HR = 6.295), DFS (P < 0.0001, HR = 5.919), and OS (P < 0.0001, HR = 4.564) in patients with RCC from the testing set (Figure 4A). This evidence concerns the gene MTAP and renal cell carcinoma.